One hundred seventy-fold increase in excretion of an FV fragment-tumor necrosis factor alpha fusion protein (sFV/TNF-α) from Escherichia coli caused by the synergistic effects of glycine and Triton X-100

Applied and Environmental Microbiology

Volumn 64, Issue 8, 1998, Pages 2869-2874

  Yang, Junbao ^a   Moyana, Terence ^a   Mackenzie, Samuel ^b   Xia, Qun ^a   Xiang, Jim ^a,c  

^a UNIVERSITY OF SASKATCHEWAN   (Canada)

^b NATIONAL RESEARCH COUNCIL CANADA   (Canada)

^c Saskatoon Cancer Center   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCINE; HYBRID PROTEIN; TRITON X 100; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; BACTERIUM CULTURE; DRUG TARGETING; ESCHERICHIA COLI; NONHUMAN; PROTEIN SYNTHESIS; RECOMBINANT DNA TECHNOLOGY;

BACTERIA (MICROORGANISMS); ESCHERICHIA COLI; NEGIBACTERIA;

EID: 0031904157     PISSN: 00992240     EISSN: None     Source Type: Journal    
DOI: 10.1128/aem.64.8.2869-2874.1998     Document Type: Article

References (29)

1. Bowden, G., and G. Georgiou. 1990. Folding and aggregation of β-lactamase in the periplasmic space of E. coli. J. Biol. Chem. 265:16760-16766.
2. Bowden, G., A. Paredes, and G. Georgiou. 1991. Structure and morphology of protein inclusion bodies in E. coli. Bio/Technology 9:725-730.
3. Buchner, J., I. Pastan, and U. Brinkmann. 1992. A method for increasing yield of properly folded recombinant fusion proteins: single-chain immunotoxins from renaturation of bacterial inclusion bodies. Anal. Biochem. 205: 263-270.
4. Chalmers, J., E. Kim, J. Telford, E. Wong, W. Tacon, M. Shuler, and D. Wilson. 1990. Effects of temperature on Escherichia coli overproducing β-lactamase or human epidermal growth factor. Appl. Environ. Microbiol. 56:104-110.
5. Claudhary, V., C. Queen, R. Junghanns, T. Waldmann, D. FitzGerald, and I. Pastan. 1989. A recombinant immunotoxin consisting of two antibody variable domains fused to Pseudomonas exotoxin. Nature 339:394-397.
6. Claudio, J., H. Suzuki, H. Kumagai, and T. Tochikura. 1991. Excretion and rapid purification of glutamyltranspeptidase from E. coli K-12. J. Ferment. Bioeng. 72:125-127.
7. Colcher, D., R. Bird, M. Roselli, and J. Schlom. 1990. In vivo tumor targeting of a recombinant single-chain antigen-binding protein. J. Natl. Cancer Inst. 82:1192-1198.
8. Forsberg, G., M. Forsgren, M. Jaki, M. Norin, C. Sterky, A. Enhorning, K. Larsson, M. Ericsson, and P. Bjork. 1997. Identification of framework residues in a secreted recombinant antibody fragment that control production level and localization in E. coli. J. Immunol. 272:12430-12436.
9. Fujiyama, K., H. Maki, S. Kinoshita, and T. Yoshida. 1995. Purification and characterization of the recombinant alginate lyase from Pseudomonas sp. leaked by E. coli upon addition of glycine. FEMS Microbiol. Lett. 126:19-24.
10. Givol, D. 1991. The minimal antigen-binding fragment of antibodies - FV fragment. Mol. Immunol. 28:1379-1386.
11. Guzman, C., G. Piatti, L. Staendner, F. Biavasco, and C. Pruzzo. 1995. Export of Bordetella pertussis serotype 2 and 3 fimbrial subunits by E. coli. FEMS Microbiol. Lett. 128:189-194.
12. Hammes, W., K. Scheifer, and O. Kandler. 1973. Mode of action of glycine on the biosynthesis of peptidoglycan. J. Bacteriol. 116:1029-1053.
13. Hsiung, H., A. Cantrell, C. Luirink, B. Oudega, A. Veros, and G. Becker. 1989. Use of bacteriocin release protein in E. coli for excretion of human growth hormone into the culture medium. Bio/Technology 7:267-271.
14. Ikura, Y. 1986. Effect of glycine and its derivatives on production and release of β-galactosidase by E. coli. Agric. Biol. Chem. 50:2747-2753.
15. King, D., O. Byron, A. Mountain, N. Weir, A. Harvey, A. Lawson, D. Baldock, S. Harding, G. Yarranton, and R. Owens. 1993. Expression, purification and characterization of B72.3 FV fragments. Biochem. J. 290:723-729.
16. Kragh-Hangen, U., M. Maire, J. Noel, and J. Moller. 1993. Transitional steps in the solubilization of protein-containing membranes and liposomes by nonionic detergent. Biochemistry 32:1648-1656.
17. Lama, J., and L. Carrasco. 1992. Expression of poliovirus nonstructural proteins in E. coli cells: modification of membrane permeability induced by 2 Å and 3 Å. J. Biol. Chem. 267:15932-15937.
18. Leduc, M., R. Kasra, and J. van Heijenoort. 1982. Induction and control of the autolytic system of Escherichia coli. J. Bacteriol. 152:26-34.
19. Matzku, S., W. Tilgen, H. Kalthoff, and E. Brocker. 1988. Dynamics of antibody transport and internalization. Int. J. Cancer 2:11-17.
20. Neugebauer, J. 1990. Detergents: an overview. Methods Enzymol. 182:239-253.
21. Pugsley, A., and M. Schwartz. 1984. Colicin E2 release: lysis, leakage or secretion? Possible role of a phospholipase. EMBO J. 3:2393-2397.
22. Qi, Y., T. Moyana, Y. Chen, and J. Xiang. 1996. Characterization of antitumor immunity derived from the inoculation of myeloma cells secreting the fusion protein RM4/IFN. Hum. Antib. 7:21-26.
23. Sawyer, J., J. Schlom, and S. Kashmiri. 1994. The effects of induction conditions on production of a soluble antitumor sFV in E. coli. Protein Eng. 7:1401-1406.
24. Shibui, T., and K. Nagahari. 1992. Secretion of a functional Fab fragment in E. coli and the influence of culture conditions. Appl. Microbiol. Biotechnol. 37:352-357.
25. Tai, M., M. Mudgett-Hunter, D. Levinson, G. Wu, E. Haber, H. Oppermann, and J. Huston. 1990. A bifunctional fusion protein containing Fc-binding fragment B of staphylococcal protein A amino terminal to antidigoxin single-chain FV. Biochemistry 29:8024-8030.
26. Wal, F., C. Hagen-Jongman, B. Oudega, and J. Luirink. 1995. Optimization of bacteriocin-release-protein-induced protein release by E. coli: extracellular production of the periplasmic molecular chaperone FaeE. Appl. Microbiol. Biotechnol. 44:459-465.
27. Xiang, J., J. Roder, Z. Pan, C. Roifman, and N. Hozumi. 1991. Modification in framework region I results in a decreased affinity of chimeric anti-TAG72 antibody. Mol. Immunol. 28:141-148.
28. Xiang, J., T. Moyana, J. Karla, T. Hamilton, and Y. Qi. 1992. Construction and characterization of a high-affinity chimeric anti-colorectal carcinoma antibody ccM4. Mol. Biother. 4:174-183.
29. Yang, J., T. Moyana, and J. Xiang. 1995. A genetically engineered single-chain FV/TNF molecule possesses the antitumor immunoreactivity of FV as well as the cytotoxic activity of tumor necrosis factor. Mol. Immunol. 32:873-881.